NIAID/DMID/CASG Central Unit
Birmingham, Alabama, 35294, United States
NCT Number: NCT00001126
The purpose of this study is to see what dose of the drug cidofovir is safe to treat laryngeal papillomatosis (warts in the throat which occur over and over) in children.
Laryngeal papillomatosis is caused by infection with a virus called human papillomavirus (HPV). At present, there is no approved drug to treat this infection. However, cidofovir is a drug effective against several viruses. Cidofovir may be able to attack the HPV virus. This study tests the safety of giving this drug to children.
Looking for future studies?
Notify Me2 year–17 year
All sexes
Interventional
Phase 1
Birmingham, Alabama, 35294, United States
Your child will be assigned randomly (like tossing a coin) to receive either cidofovir or placebo (an inactive substance). Neither you nor your doctor will know which your child is receiving. Your child will undergo a total of 6 bronchoscopic procedures, which involves placing a tube down your child's throat so that the warts can be seen and treated. The warts will be removed by laser or other procedures and the study drug injected. Study drug will be injected at the sites of all newly removed warts and warts which were removed during earlier study visits. This procedure will be performed every other week. Blood and urine tests will also be performed at this time. Your child will be under general anesthesia during each procedure and will be in the surgery unit for about 6 to 8 hours. Your child will also have to be seen by the doctor 2 days after the procedure. Your child will be followed for a total of 5 years to make sure he/she develops normally and to monitor any side effects of cidofovir. Follow-up visits will take place at Months 3, 6, and then once every 6 months through Year 5. If necessary, laser or other procedures will be performed at these visits to remove any warts.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Your child may be eligible for this study if he/she:
Exclusion criteria
Your child will not be eligible for this study if he/she:
National Institute of Allergy and Infectious Diseases (NIAID)
Nih
A Phase I/II Evaluation of Cidofovir Therapy For Recurrent Laryngeal Papillomatosis in Children
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05625308
Cervix Lesion, Neoplasms
Roma, Italy
View Trial DetailsNCT00006444
Blood-Borne Infections, Communicable Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT01827423
Nasal Diseases, Nasal Polyps
Ostrava, Moravian-Silesian Region, Czechia
View Trial DetailsNCT00001603
Behavior, Carcinoma
Bethesda, Maryland, United States
View Trial Details